Effect of Empagliflozine on fatty liver

Phase 3

• Conditions: on alcoholic fatty liver.; Fatty (change of) liver, not elsewhere classified; K76.0

• Registration Number: IRCT20240326061366N1
• Lead Sponsor: Yasouj University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 27 May 2024

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Ages greater than 18
Fatty liver sonography findings
ALT levels greater than 33 in non diabetic male and greater than 25 in non diabetic female
Personal interest to participate
Consumption of non or less than 20 grams of alcohol per day in female and non or less than 30 grams of alcohol per daY in male
No history of malignancies,cardiovascular respiratory and renal complications,
No history of weight loss or weight loss surgery
No history of drug consumption and no history of metabolic and endocrine complications
No history of liver enhancing drugs such as Vit E,Liver goal,Liver med ...

Exclusion Criteria

No interest in participating
Pregnancy or breastfeeding in female
No drug use compatibility
Allergy to Empagliflozine
Participating in other clinical studies

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Alanine transaminase. Timepoint: Before the start of study and 8 weeks after intervention. Method of measurement: Calorimetry withhitachi autoanalyzer 7020.

Secondary Outcome Measures

Name	Time	Method
C reactive protein. Timepoint: Before intervention and 8 weeks after the start of intervention. Method of measurement: Laser nephelometry.